Improvement in Survival After Treatment for Metastatic Bone Disease: An International Trend-Analysis

Rogers D¹, Levin A¹, Raad M¹, Rivera J², Wedin R³, Laitinen M⁴, Sørensen M⁵, Hilton T⁶, Morris CM¹, Forsberg J.¹

¹Department of Orthopaedic Surgery, Johns Hopkins Hospital, Baltimore, MD
   Davis Rogers: droger23@jhmi.edu
   Adam Levin: alevin25@jhmi.edu
   Micheal Raad: mraad2@jhmi.edu
   Carol Morris: cmorri61@jhmi.edu
   Jonathan Forsberg: jforsbe1@jhmi.edu

²Department of Defense Osseointegration Program, Henry M. Jackson Foundation, Bethesda, MD
   Julio Rivera: julio.rivera85@gmail.com

³Department of Orthopaedic Surgery, Karolinska University Hospital, Karolinska Intitutet, Stockholm Sweden
   Rikard Wedin: rikard.wedin@ki.se

⁴Department of Orthopaedics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
   Minna Laitinen: minna.laitinen@hus.fi

⁵Department of Orthopaedics, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark
   Michala Sørensen: michala.skovlund@gmail.com

⁶Department of Orthopaedics, Groote Schuur Hospital, Cape Town, South Africa
   Thomas Hilton: tlhilton@hotmail.com

Financial Disclosures:
   Please refer to the AAOS Disclosure Program for current Author Disclosures

Presenter:
   Davis Rogers, droger23@jhmi.edu

Level of Evidence: III

Background

Estimating life expectancy in patients with metastatic bone disease (MBD) is important for framing management options to patients. The decision to operate, both if and how, is at least partially related to the individual patient’s estimated survival. Various attempts have been made to prospectively predict survival in MBD, including prognostic scoring systems, advanced statistical modeling, as well as simply relying on subjective surgeon predictions. As modern surgical techniques have allowed for an increasing complexity of operative management, it is important for the Orthopaedic community to reflect on its current trajectory to ensure that the associated risks and costs of surgery are leading to tangible results. Short term results have been investigated, indicating that fracture prevention and prophylactic treatment of extremity metastases can reduce metastatic complications and
improve survival rates. Although there have been isolated single-institution reports investigating survival rates in MBD, there has yet to be a worldwide analysis on if and how patient survival has changed in this context.

The goal in treating skeletal metastasis is to maximize both function and quality of life for the greatest amount of time; in doing so, we must balance expectations. Falsely optimistic predictions risk unnecessary perioperative morbidity and mortality; falsely pessimistic predictions risk insufficient biomechanical durability and complicated revisions. Considering the medical costs and significant risks associated, providing evidence regarding the true change in survival rates with respect to surgery can provide physicians and patients with more accurate information to make evidence-based decisions.

Questions/Purpose

Our primary aim is to demonstrate current rates and long-term trends in survival rates for patients with operatively-managed MBD. Secondary aims include comparing survival rates across multiple primary oncological diagnoses. We hypothesized that survival for surgically-managed patients treated for symptomatic MBD will increase progressively over the past decades.

Patients and Methods

Initially, we queried the International Bone Metastasis Registry (IBMR) to identify all patients treated for MBD, regardless of institution. To provide historical context, we also used data that supported the development and validation of the PATHFx survival models, from centers that now contribute data to the IBMR. Inclusion criteria consists of adult patients who underwent treatment, including surgery and/or radiotherapy, for MBD to the axial and appendicular skeleton. We excluded records lacking the oncologic diagnosis, date of surgery, or overall survival. Patients were additionally divided by primary malignancy for the most common diagnoses. For each record, we calculated overall survival in months. For patients who were treated more than once, only the first surgery for metastases were accounted for in the survival analysis.

We grouped records according to three time periods: Period I (2000-2010), Period II (2010-2020), and Period III (2020-Present). Cumulative survival with 95% confidence intervals by diagnosis group were portrayed using Kaplan-Meier curves; a Mantel-Cox log-rank test was applied to test for statistically significant differences between groups. All P-values ≤0.05 were considered significant.

Results

A total of 3061 patients were included in this study, 1099 from the IBMR and 1962 from historical data. No patients were excluded as all had prerequisite data of overall survival. Of these patients with MBD, 20% were due to breast cancer, 15% lung, 13% myeloma, 11% renal, 9% prostate, 4% sarcoma, 3% colorectal, 3% melanoma, 1% thyroid, and 21% other. Using Mantel-Cox log-rank tests applied to Kaplan-Meier curves of cumulative survival rates, patients included in Period II (2010-202) demonstrated increased survival rates compared to Period II (p-value <0.0001) (Figure 1). Median survival had not been reached for Period III, however there was an apparent trend towards increased survival rates compared to both Period II and I (Figure 1). Subgroup analysis demonstrated a significant increase in survival rates over time periods for prostate, thyroid, melanoma, lung, and breast (all p-value < 0.0001), but not necessarily for multiple myeloma, or kidney cancer.

Conclusions

Cumulative survival rates for patients after treatment for MBD has improved over time. This was seen in nearly all disease-specific subgroups. Although the changes are likely due to improvements in medical management, orthopaedic decision-making should involve methods to estimate life expectancy based on objective information. In doing so, more durable constructs should be strongly considered if applicable.
Figures

Figure 1: Kaplan-Meyer curve of overall survival rates for all patients, separated and compared by time period. Using Mantel-Cox log-rank testing, there was a statistically significant increase in survival rates found in patients during Period II compared to Period I (p<0.0001). Median survival has not yet been obtained for Period III.